Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Bicyclic azetidines target acute and chronic stages of Toxoplasma gondii by inhibiting parasite phenylalanyl t-RNA synthetase

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Key needs to accelerate Cryptosporidium drug development.

Structural overlays help to rationalize the SAR for 18 , 19 and 23

Structure of the N-terminal region of ScNMT. A, molecular surface of

Rudimentary Structure-Activity-Relationship study of the MMV Pathogen Box compound MMV675968 (2,4-diaminoquinazoline) unveils novel inhibitors of Trypanosoma brucei brucei DHFR enzyme

Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite

impact and imprinting of S-palmitoylation at the genomic scale. a

Biochemical and structural evidence for the NMT activity on lysine a

Frontiers Cryptosporidium parvum Pyruvate Kinase Inhibitors With in vivo Anti-cryptosporidial Efficacy

Targeting RNA structures with small molecules